Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Neoplasms 9Ovarian Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Multiple Myeloma 2Stomach Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms by Site 1Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Colorectal Neoplasms 1Bites and Stings 1Adenocarcinoma 1

Interventions

Gemcitabine 153Fluorouracil 45Capecitabine 45130-nm albumin-bound paclitaxel 43Oxaliplatin 42Albumin-Bound Paclitaxel 39Leucovorin 31Erlotinib Hydrochloride 30pembrolizumab 23Radiotherapy 22Irinotecan 22Radiosurgery 20Bevacizumab 19Docetaxel 17Cyclophosphamide 17Taxes 13Cisplatin 13Cetuximab 13folfirinox 12Nivolumab 11Surgical Procedures, Operative 7Paclitaxel 7Ipilimumab 7dehydroftorafur 6Standard of Care 6Radiation 6Magnetic Resonance Spectroscopy 6spartalizumab 5ruxolitinib 5durvalumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Pancreatic Neoplasms × dostarlimab × Clear all
NCT04409002 2025-08-15

Niraparib + Dostarlimab + RT in Pancreatic Cancer

Massachusetts General Hospital

Phase 2 Completed
18 enrolled 11 charts
Gastrointestinal

Pancreatic Neoplasms

NCT04493060 2025-08-07

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

Mayo Clinic

Phase 2 Completed
22 enrolled 17 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡